Read by QxMD icon Read

Metaplastic breast cancer

Na Zhou, Cong Min Liu, He Lei Hou, Chuan Tao Zhang, Dong Liu, Guan Qun Wang, Ke Wei Liu, Jing Juan Zhu, Hong Ying Lv, Tian Jun Li, Xiaochun Zhang
Spindle cell carcinoma of the breast is a rare subtype of metaplastic carcinoma, and no effective chemotherapy special for metaplastic carcinoma exists until now. As spindle cell carcinomas of the breast are typically "Triple Negative", endocrine therapy and molecular therapy targeted to Her2 might not be favorable, resulting in poor prognosis. Apatinib is currently being tested in patients with breast or lung cancers. Here we report a successful case using Apatinib to treat spindle cell carcinoma of breast...
October 11, 2016: Oncotarget
Matteo Ghilli, Donatella M Mariniello, Giovanni Fanelli, Francesca Cascione, Andrea Fontana, Agostino Cristaudo, Anna Cilotti, Adelaide M Caligo, Giampiero Manca, Livio Colizzi, Antonio G Naccarato, Manuela Roncella
No abstract text is available yet for this article.
August 30, 2016: Clinical Breast Cancer
N Merali, M Yousuff, V Pronisceva, A Poddar
Paraneoplastic syndrome affects less than 1% of cancer patients. Diagnosis of paraneoplastic syndrome with neurological presentation requires screening for an underlying malignancy, including a complete history, physical examination and imaging studies. Treatment often results in symptom stability, rather than improvement. Paraneoplastic polymyositis can precede or instantaneously occur at diagnosis or treatment of a primary tumour, while neurological symptoms can persist even following cancer treatment. We report a rare case of metaplastic breast carcinoma with an unusual presentation of paraneoplastic polymyositis...
September 23, 2016: Annals of the Royal College of Surgeons of England
Li-Ching Fan, Yung-Ming Jeng, Yueh-Tong Lu, Huang-Chun Lien
In addition to contraction, myoepithelia have diverse paracrine effects, including a tumor suppression effect. However, certain myoepithelial markers have been shown to contribute to tumor progression. Transforming growth factor-β (TGF-β) is involved in the transdifferentiation of fibroblasts to contractile myofibroblasts. We investigated whether TGF-β can upregulate potential myoepithelial markers, which may have functional and clinicopathological significance in breast cancer. We found that TGF-β induced SPOCK1 expression in MCF10A, MCF12A, and M10 breast cells and demonstrated SPOCK1 as a novel myoepithelial marker that was immunolocalized within or beneath myoepithelia lining ductolobular units...
2016: PloS One
Magdalena L Plasilova, Brandon Hayse, Brigid K Killelea, Nina R Horowitz, Anees B Chagpar, Donald R Lannin
The aim of this study was to determine the features of triple-negative breast cancer (TNBC) using a large national database. TNBC is known to be an aggressive subtype, but national epidemiologic data are sparse. All patients with invasive breast cancer and known molecular subtype diagnosed in 2010 to 2011 were identified from the National Cancer Data Base (NCDB). Patients with and without TNBC were compared with respect to their sociodemographic and clinicopathologic features. TNBC was present in 38,628 of 295,801 (13%) female patients compared to 185 of 3136 (6%) male patients (P < 0...
August 2016: Medicine (Baltimore)
Jessica Edenfield, Christine Schammel, Justin Collins, David Schammel, W Jeff Edenfield
INTRODUCTION: Metaplastic breast carcinoma (MBC) is a rare and aggressive histologic subtype of breast cancer comprising approximately 0.5% to 5.0% of all invasive breast cancers with a poor prognosis and limited therapeutic options. PATIENTS AND METHODS: We investigated MBC at our institution to evaluate outcomes and investigate the molecular profile of our cohort to determine the presence of mutations for which there are targeted therapies. RESULTS: We found our cohort to consist mainly of the matrix-producing variant (72%) with 48% having the stereotypical estrogen receptor-negative/progesterone receptor-negative/human epidermal growth factor receptor-2-negative phenotype...
July 25, 2016: Clinical Breast Cancer
Upasana Joneja, Semir Vranic, Jeffrey Swensen, Rebecca Feldman, Wangjuh Chen, Jeffrey Kimbrough, Nianqing Xiao, Sandeep Reddy, Juan Palazzo, Zoran Gatalica
AIMS: Metaplastic breast carcinoma (MBC) is a rare subtype of breast carcinoma less responsive to conventional chemotherapy than ductal carcinoma. In molecular terms, MBCs usually cluster with triple-negative breast cancers (TNBCs), but have a worse prognosis than TNBCs. Studies investigating MBCs for specific biomarkers of therapy response are rare and limited by the methodological approaches. The aim of the present study was to characterise MBCs on a molecular level and test programmed death-ligand 1 (PD-L1) biomarker expression in MBCs for future therapeutic interventions...
August 16, 2016: Journal of Clinical Pathology
Ioannis-Georgios Tzanninis, Elias A Kotteas, Ioannis Ntanasis-Stathopoulos, Panagiota Kontogianni, George Fotopoulos
Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic, immunohistochemical, and molecular features. Resistance to systemic therapies, whether chemotherapy or hormonal therapy, is among its main characteristics, which in turn explains the poor prognosis and renders its management a challenge. Thus, the scope of the present review is to discuss the current therapeutic strategies for MBC in clinical practice and the corresponding outcomes and to suggest possible directions for future research...
June 15, 2016: Clinical Breast Cancer
S Sherwell-Cabello, A Maffuz-Aziz, B Hernández-Hernández, V Bautista-Piña, S Labastida-Almendaro, S Rodríguez-Cuevas
BACKGROUND: Metaplasic carcinoma of the breast was initially described by Huvos in 1974. It is a rare and aggressive entity characterized by the presence of mesenchymal and epithelial components. OBJECTIVE: To know the incidence and biologic behaviour of the metaplasic carcinoma of the breast at the Instituto de Enfermedades de la Mama, FUCAM, AC. METHODS: Data on women diagnosed with metaplasic carcinoma of the breast between January 2005 and December 2014 was collected by retrospectively reviewing in FUCAM...
March 2016: Ginecología y Obstetricia de México
R Benson, R Madan, P K Julka, G K Rath
PURPOSE: Metaplastic carcinoma of breast (MCB) is a rare histological subtype of breast carcinoma and accounts for less than 1 percent of the total breast cancer cases. Here we are reporting a series of seven patients of MCB from single institute along with review of literature. MATERIAL AND METHODS: Patients records from January 2008 to August 2014 were retrieved to search for MCB patients. A etrospective review was conducted to document the clinicopathological features, treatment and outcomes of these patients...
May 2016: Gulf Journal of Oncology
Fiona Langlands, Eleanor Cornford, Emad Rakha, Barbara Dall, Eleanor Gutteridge, David Dodwell, Abeer M Shaaban, Nisha Sharma
OBJECTIVES: To review the clinical presentation, baseline imaging features, surgical management and final surgical pathology of metaplastic carcinoma of the breast. METHODS: A total of 71 cases were identified over a 10year period from two major UK breast cancer institutions. Imaging at diagnosis including mammography, ultrasound, MRI and CT scans and histological diagnosis were reviewed. Follow-up data including local and systemic recurrence was retrieved. RESULTS: Of the 71 cases, 60(84...
June 1, 2016: British Journal of Radiology
Fabian Leo, Stephan Bartels, Lavinia Mägel, Theodor Framke, Guntram Büsche, Danny Jonigk, Matthias Christgen, Ulrich Lehmann, Hans Kreipe
Metaplastic breast carcinoma (MBC) comprises a heterogeneous group of tumors with difficult to predict biological behavior. A subset of MBC, characterized by spindle-shaped tumor cells with a myoepithelial-like immunophenotype, was entered into a retrospective study (n = 42, median follow-up time 43 months). Molecular parameters (DNA sequences of mutation hot spots in AKT1, ALK, APC, BRAF, CDH1, CTNNB1, EGFR, ERBB2, FBXW7, FGFR2, FOXL2, GNAQ, GNAS, KIT, KRAS, MAP2K1, MET, MSH6, NRAS, PDGFRA, PIK3CA, PTEN, SF3B1, SMAD4, SRC, SRSF2, STK11, TP53, and U2AF1; copy numbers for EGFR, c-myc, FGFR, PLAG, c-met) were assessed...
August 2016: Virchows Archiv: An International Journal of Pathology
Ashley Cimino-Mathews, Sangita Verma, Maria Cristina Figueroa-Magalhaes, Stacie C Jeter, Zhe Zhang, Pedram Argani, Vered Stearns, Roisin M Connolly
OBJECTIVES: Metaplastic breast carcinomas (MBCs) are rare, aggressive cancers lacking targeted therapy. Here, we review the clinicopathologic features, treatment, and outcomes of patients with MBC treated at our institution. METHODS: We searched clinical and pathology databases for patients with histologically confirmed MBC from 1999 to 2012. We estimated survival probabilities using the Kaplan-Meier method and evaluated prognostic factors using Cox regression. RESULTS: Forty-five cases were identified, including chondroid (24%), spindled (20%), sarcomatoid (16%), squamous (11%), and mixed (29%) histologic subtypes...
March 2016: American Journal of Clinical Pathology
Jingjing Wu, Shizhen Zhang, Jinlan Shan, Zujian Hu, Xiyong Liu, Lirong Chen, Xingchang Ren, Lifang Yao, Hongqiang Sheng, Ling Li, David Ann, Yun Yen, Jian Wang, Xiaochen Wang
High mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of biological processes and is upregulated in several tumors. Here, we collected 273 breast cancer (BC) specimens as a training set and 310 specimens as a validation set to examine the expression of HMGA2 by immunohistochemical staining. It was found that HMGA2 expression was significantly positively correlated with advanced tumor grade and poor survival. Subgroup analysis indicated that high level of HMGA2 was significantly correlated with poor prognosis, especially in the subgroups of stage II-III, low pathological grade and non-triple negative breast cancer cases...
July 1, 2016: Cancer Letters
Renu Gahlaut, Aneliese Bennett, Hiba Fatayer, Barbara J Dall, Nisha Sharma, Galina Velikova, Tim Perren, David Dodwell, Mark Lansdown, Abeer M Shaaban
PURPOSE: To assess the effect of neoadjuvant chemotherapy (NACT) on breast cancer characteristics, hormone receptors and human epidermal growth factor receptor 2 (HER2) expression and whether testing should be repeated on residual tumours. MATERIAL AND METHODS: Patients with primary operable breast cancer who received NACT at a single United Kingdom tertiary referral centre were included. Tumour type, grade (including details of mitotic grade, tubule formation and pleomorphism), oestrogen receptor (ER), progesterone receptor (PR) and HER2 status were compared between pre-treatment and post-treatment residual samples using tissue microarrays...
June 2016: European Journal of Cancer
Funmilayo I Tade, Michael A Cohen, Toncred M Styblo, Oluwaseun A Odewole, Anna I Holbrook, Mary S Newell, Bital Savir-Baruch, Xiaoxian Li, Mark M Goodman, Jonathon A Nye, David M Schuster
UNLABELLED: The purpose of this study was to explore the uptake of the synthetic amino acid analog PET radiotracer anti-3-(18)F-FACBC ((18)F-fluciclovine) in breast lesions with correlation to histologic and immunohistochemical characteristics. METHODS: Twelve women with breast lesions underwent 45-min dynamic PET/CT of the thorax after intravenous administration of 366.3 ± 14.8 (337.44-394.05) MBq of (18)F-fluciclovine. Uptake in the primary lesions at 4 representative time points (5, 17, 29, and 41 min) after injection were correlated with histologic, imaging, and clinical findings...
September 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Andrew Evans, Yee Ting Sim, Kim Thomson, Lee Jordan, Colin Purdie, Sarah J Vinnicombe
PURPOSE: To define the shear wave elastography (SWE) characteristics of breast cancer histological types by size in a large cohort. METHODS: Consecutive patients with US visible masses underwent SWE. All those with confirmed invasive breast cancer were included in the study. Histologic type was ascertained from core biopsy and surgical resection specimens. For each type, mean and median values for Emean and Emax were ascertained. Commoner tumour types were further analysed by invasive size...
April 2016: Breast: Official Journal of the European Society of Mastology
M Asunción Fernández Pérez, Isabel Viqueira Rodriguez, Alberto Tello Royloa, Javier Martínez Guisasola
BACKGROUND: Metaplastic breast carcinoma is an uncommon type of breast cancer that usually appears as a large, fast growing breast lump. CASE REPORT: We report 3 cases of metaplastic breast carcinoma presented at our clinic in 2014. The mean age at diagnosis was 67.3 years. 1 patient presented with a fast growing, large mass detected by herself. However, in the other 2 patients, the nodule was approximately 1.5 cm in size, not fast growing, and was detected on mammography...
December 2015: Breast Care
Lamya Hamad, Thaer Khoury, Karen Vona, Jill Nestico, Mateusz Opyrchal, Kilian E Salerno
Female breast cancer accounts for 14% of all new cancer cases in the United States. Metaplastic breast carcinomas (MpBC) are less than 1% of all mammary tumors. Limited clinical information exists on the prognosis and treatments for MpBC due to its rarity and the histological diversity of the tumor cells. We report a case of metastatic MpBC with osseous differentiation who had a marked response to liposomal doxorubicin. This 54-year-old female presented with a 2.5 x 2.6 cm oval-shaped irregularly marginated density in the outer lower quadrant of the left breast, cT2N0M0...
2016: Curēus
Maria Vittoria Dieci, Veronika Smutná, Véronique Scott, Guangliang Yin, Ran Xu, Philippe Vielh, Marie-Christine Mathieu, Cécile Vicier, Melanie Laporte, Francoise Drusch, Valentina Guarneri, Pierfranco Conte, Suzette Delaloge, Ludovic Lacroix, Olivia Fromigué, Fabrice André, Celine Lefebvre
Little is known about mutational landscape of rare breast cancer (BC) subtypes. The aim of the study was to apply next generation sequencing to three different subtypes of rare BCs in order to identify new genes related to cancer progression. We performed whole exome and targeted sequencing of 29 micropapillary, 23 metaplastic, and 27 pleomorphic lobular BCs. Micropapillary BCs exhibit a profile comparable to common BCs: PIK3CA, TP53, GATA3, and MAP2K4 were the most frequently mutated genes. Metaplastic BCs presented a high frequency of TP53 (78 %) and PIK3CA (48 %) mutations and were recurrently mutated on KDM6A (13 %), a gene involved in histone demethylation...
February 2016: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"